Financial Uncertainty Casts Doubt On MannKind’s Inhalable Epinephrine Plans
The California company wants to offer competition to Mylan, but it is already facing struggles with its inhalable insulin product.
Los Angeles Times:
MannKind Developing Inhalable Epinephrine To Challenge Mylan's EpiPen
A Valencia drugmaker that has tried to convince diabetics to inhale rather than inject their insulin is working on a product that will make a similar pitch to a new group of patients: severe allergy sufferers who rely on Mylan Pharmaceuticals’ pricey EpiPen. Even as it struggles to ramp up sales of its Afrezza inhalable insulin, MannKind Corp. is now in the early stages of developing an inhalable form of epinephrine that aims to take market share from the injectable version at the center of a storm over drug pricing. (Koren, 9/6)
In other drug pricing news —
Allergan Vows Limited Price Hikes, Says 'Outliers' Deter Research
The chief executive officer of Allergan Plc said his company would limit annual price increases on its prescription drugs, and that "outlier" drugmakers that have imposed huge price increases on their products were scaring off venture capital investors. Allergan, the maker of such products as Botox, plans to raise prices no more than once a year and keep price hikes to no more than low-to-mid-single-digit percentages, slightly above the current annual rate of inflation, CEO Brent Saunders said on Tuesday. (Pierson, 9/6)